Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Basic Physician's Training Monash > IBs, MABs, and fancy things > Flashcards

IBs, MABs, and fancy things Flashcards

1
Q

Adalimumab: Target and disease

A

Anti-TNF

RA, Psoriatic, arthritis, Ank spond

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Afatinib: Target and disease

A

EGFR inhibitor

NSCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Alemtuzumab: Target and disease

A

Anti-CD52
MS, CML, cutaneous T cell lymphoma, transplant induction

AE: CMV, Hypersensitivity, profound lymphopenia >12mo, Autoimmune diseases (ITP, thyroid)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Anakinra: Target and disease

A

IL1 blockade
Autoinflammatory blockade
Typically in still’s disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Axitinib: Target and disease

A

VEGF mainly, PDGFRB, c-KIT

2nd line RCC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Basiliximab: Target and disease

A

Anti-IL2R – Anti-CD25

Renal transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Belatacept: Target and disease

A

CTLA4 fused with Fc, blocks T cell co-stimulation

Renal transplant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Belimumab: Target and disease

A

Anti-BLys/BAFF

SLE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Benralizumab: Target and disease

A

Anti-IL5 receptor alpha

Asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Bevacizumab: Target and disease

A

Anti-VEGF
Colorectal, ovarian, CNS, cancer, proliferative diabetic retinopathy (intravitreal inj)
AE: HTN, GN, poor wound healing, thrombosis, nasal septal perforation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Bezlotoxumab: Target and disease

A

Anti-C.Difficile toxin B

Preventing C. Diff recurrence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Blinatumomab: Target and disease

A

Bi-specific T-cell engaging antibody
Engages CD3 on T-cell to CD19 on B cell
ALL relapse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Bortezomib (Valcade): Target and disease

A

Inhibit NF-kappaB
Multiple myeloma
AE Neuropathy, thrombocytopaenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Brentuximab: Target and disease

A

Anti-CD30

Hodgkin’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Brodalumab: Target and disease

A

Anti-IL17R

Psoriasis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Canakinumab: Target and disease

A

Anti-IL1b

RA, Autoinflammatory disease, gout

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Certolizumab: Target and disease

A

Anti-TNF
Crohn’s, RA, psoriatic, Ank spond, Crohn’s
Does not cross placenta

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Cetuximab: Target and disease

A

EGFR inhibitor
Met CRC (KRAS wild type), head and neck SCC
AE: Acneiform rash, diarrhoea, ILD, conjuctivitis, electrolytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Crizanlizumab: Target and disease

A

PSGL1

Sickle-cell crisis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Crizotinib: Target and disease

A

ALK and ROS-1
NSCLC
Poor cns penetrance
AE: visual phenomenon, bradycardia, hepatitis, pneumonitis, N+V+D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Dabrafenib: Target and disease

A

BRAF inhibitor

BRAF positive melanoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Dasatinib: Target and disease

A

BCR-ABL
2nd line in CML
AE: PLT dysfunction, pleural effusion, prolonged QT, diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Denosumab: Target and disease

A

RANK-L inhibitor
Osteoporosis
Prevents osteoclast maturation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Eculizumab: Target and disease

A

Anti-C5
PNH, aHUS
AE; Meningitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Eltrombopag: Target and disease

A

TPO receptor agonist

ITP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Erlotinib: Target and disease

A

EGFR inhibitor
NSCLC
AE: acne, diarrhea, pneumonitis, hepatitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Evolocumab: Target and disease

A

PCSK9 inhibitor
Increases hepatic cholesterol uptake
Hypercholesterolaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Etanercept: Target and disease

A

TNF blockade

RA, Psoriatic, ank spond

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Gefitinib: Target and disease

A

EGFR inhibitor

NSCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Golimumab: Target and disease

A

Anti-TNF

RA, psoriatic, ank spond, UC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Ibritumomab: Target and disease

A

Anti-CD20 bound to radioisotope

Non-hodgkin’s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Ocrelizumab: Target and disease

A

Anti-CD20

MS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Ibrutinib: Target and disease

A 
BTK inhibitor (B-cell)
CLL, Waldenstrom's, mantle cell, marginal zone, Chronic GVHD
AE: AF, diarrhoea, platelet dysfunction, fluid retention
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Idelalisib: Target and disease

A

P13K inhibitor
2nd line CLL
Non hodgkins lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

Idarucizumab: Target and disease

A

Dabigatran reversal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

Imatinib: Target and disease

A

BCR-ABL and cKIT mutations
CML, GIST, ALL
Hypereosinophilia with FGFR1/PDGFR alpha mutation
AE: muscle cramps, maculopapular rash, fatigue, pleural effusions/oedema

37
Q

Infliximab: Target and disease

A

Anti-TNF
Crohn’s, other stuff
AE: Serious infection, TB activation, increased risk of skin caner, demyelinating disease flare

38
Q

Ipilimumab: Target and disease

A

Anti-CTLA4
Metastatic melanoma
Auto-immune AE, more than PD1

39
Q

Ixekizumab: Target and disease

A

Anti-IL17a

Psoriasis, spondyloarthropathies

40
Q

Lapatinib: Target and disease

A

HER2
Her2+ breast Ca
AE; Hand foot syndrome

41
Q

Mepolizumab: Target and disease

A

Anti-IL5

Eosinophilic asthma

42
Q

Natalizumab: Target and disease

A

Anti-a4 integrin
MS
AE; PML

Brain homing T cells express alpha 4 beta 1

43
Q

Nilotinib: Target and disease

A

BCR-ABL inhibitor
2nd line CML
off-label GIST
AE: long QT, pancreatitis long term cardiovascular, PAH, inhibition of platelet function

44
Q

Nintedanib: Target and disease

A

VEGFR, FGFR
IPF
AE; Diarrhoea, deranged LFT

45
Q

Nivolumab: Target and disease

A

Anti-PD1
Melanoma, NSCLC
Pneumonitis/thyroiditis more than CTLA4

46
Q

Obinutuzumab: Target and disease

A

Anti-CD20
CLL
Follicular lymphoma

47
Q

Ofatumumab: Target and disease

A

Anti-CD20

Refractory CLL

48
Q

Omalizumab: Target and disease

A

Anti-IgE

Asthma

49
Q

Olaparib: Target and disease

A

PARP inhibitor
BRCA mutant high grade serous ovarian, fallopian tube, primary peritoneal, breast cancer
SE: myelosuppression, nausea, fatigue

50
Q

Osimertinib: Target and disease

A

EGFR inhibitor - T790M

2nd line NSCLC if T790M +ve

51
Q

Palbociclib: Target and disease

A

CDK4/6 inhibitor
Metastatic ER+ breast cancer
AE: neutropaenia

52
Q

Panitumumab: Target and disease

A

Anti-EGFR

CRC

53
Q

Pazopanib: Target and disease

A

VEGF, PDGFR, KIT
RCC
Sarcoma

54
Q

Pembrolizumab: Target and disease

A

Anti-PD1

Melanoma, NSCLC (PDL1>50%)

55
Q

Durvalumab: Target and disease

A

Anti-PDL1

stage III NSCLC

56
Q

Pertuzumab: Target and disease

A

Anti-HER2/HER3
Metastatic HER2+ breast cancer
Minimal benefit in adjuvant

57
Q

Ponatinib: Target and disease

A

BCR-ABL
3rd line CML - targets t315i mutation
AE: rash, pancreatitis, vascular events

58
Q

Ramucirumab: Target and disease

A

Anti-VEGF

Gastric cancer

59
Q

Reslizumab: Target and disease

A

Anti-IL5

Asthma

60
Q

Rituximab: Target and disease

A

Anti-CD20

Non-hodgkin’s, many others

61
Q

Romosozumab: Target and disease

A

Sclerostin inhibitor

Osteoporosis

62
Q

Ruxolitinib: Target and disease

A

Jak1/2 inhibitor

Myelofibrosis, PRV (resistant to hydroxyurea)

63
Q

Secukinumab: Target and disease

A

Anti-IL17

Psoriasis

64
Q

Siltuximab: Target and disease

A

Anti-IL6

Castleman disease

65
Q

Sorafenib: Target and disease

A

VEGFR2/3, PDGFR, C-raf>B-raf, KIT

RCC, HCC, Thyroid cancer

66
Q

Sunitinib: Target and disease

A

FGF, PDGFR, RET< FLT3, VEGFR1/2, c-KIT
GIST, RCC, Pancreatic NET
AE: MAHA/HUS/TTP, myelosuppression, GI toxicity, hand/foot syndrome, hepatotoxicity, pancreatitis, cardiotoxicity

67
Q

Tocilizumab: Target and disease

A

Anti-IL6
RA, GCA
AE: Bowel perforation

68
Q

Tofacitinib: Target and disease

A

JAK3
RA, UC
AE: Shingles

69
Q

Trametinib: Target and disease

A

MEK1/2

Melanoma (BRAF positive

70
Q

Trastuzumab: Target and disease

A

HER2

HER2+ breast Ca

71
Q

TDM-1: Target and disease

A

Also known as Trastuzumab/emtansine
HER2 mab with chemo
2nd line HER2+ breast Ca

72
Q

Ustekinumab: Target and disease

A

Anti IL12/23 (p40 subunit)
Crohn’s, psoriasis
Spondyloarthropathies (not for axial disease)

73
Q

Vedolizumab: Target and disease

A

Anti-a4b7 integrin
UC, Crohn’s (better in UC)

Gut homing T cells express a4b7

74
Q

Vemurafenib: Target and disease

A

BRAF inhibitor
BRAF pos melanoma
AE: Photosensitivity, arthralgia

75
Q

Andaxanet alfa: Target and disease

A

Reversal of apixaban, rivaroxaban

76
Q

Ceritinib: Target and disease

A

2nd line ALK inhibitor

Nsclc

77
Q

Alectinib: Target and disease

A

2nd line ALK inhibitor

Nsclc

78
Q

Romiplostim: Target and disease

A

TPO receptor antagonist

ITP not suitable for splenectomy or post splenectomy

79
Q

Emicizumab: Target and indication

A

Mimics factor VIII (Biallelic antibody to factor IX and X)

Severe Haemophilia A

80
Q

Venetoclax: Target and disease

A

BCL2

CLL, MPN1 positive AML

81
Q

Regorafenib: Target and disease

A

VEGF, KIT, TIE2, PDGFR

CRC (2nd/3rd line), GIST (2nd line)

82
Q

Ribociclib: Target and disease

A

CDK4/6 inhibitor
Metastatic ER+ breast cancer
AE: neutropaenia

83
Q

Fingolimod: Target and disease

A

Downregulates sphingosine-1-phosphate receptors, Decreases ability of lymphocytes to enter CNS
AE: bradycardia/heart block, macular oedema

84
Q

Erenumab: Target and disease

A

Recombinant human monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP) vasodilation by blocking CGRP receptors
Migraine Prophylaxis

85
Q

Icatibant: Target and indication

A

Bradykinin receptor antagonist

Hereditary angioedema treatment of attacks

86
Q

Rilonacept: Target and indication

A

IL-1 Trap

Dimeric fusion protein incorporating components of IL-1R

Severe RA
Autoinflammatory diseases

87
Q

Abatacept: Target and indication

A

CTLA-4 bound to Fc end of Ig=B7 blocker
Prevents T cell activation

RA

88
Q

Dupilumab: Target and indication

A

Anti IL-4 receptor alpha

Atopic dermatitis

89
Q

Daratumumab: Target and indication

A

Anti-CD38
Myeloma

Interference with indirect anti globulin tests.
Need to send extended red blood cell phenotype and RBC antibody screen before 1st dose

Basic Physician's Training Monash (16 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions